Ysios Capital invests $5 millions in pharmaceutical company Kala
This is the eleventh investment of the Ysios BioFundI, which has just opened a new "biotech" fund endowed with $100 millions
Catalan venture capital firm Ysios Capital has invested $5 millions in US company Kala Pharmaceuticals. With this investment, Ysios led the $22.5-millions round of funding, which will allow Kala to move forward with clinical trials on their products to treat eye disease based on MPP technology (Mucus Penetrating Particle).
This is the eleventh and final investment by Ysios under BioFundI, which was created in 2008 with $69 millions in committed capital. Now that it has closed out the first fund, Ysios has begun fundraising for BioFundII, the new fund devoted to supporting European and North-American companies in the life sciences sector. BioFundII will have $100 millions to help develop disruptive products, platforms and technology in medical technology or diagnostics.
Ysios Capital is a venture capital management firm based in Barcelona that was created in 2008. They specialize in health and life sciences companies from the biotechnology industry. In September 2013, they sold Swiss medical-technology company Endosense to US St. Jude Medical for $345 millions, and in 2011 sold BioVex to Amgen for $1,000 millions.
More information is available on the Ysios website and in their press release.
- Related news (05/11/2013)
- Related news (16/09/2013)